Fluphenazine IM Injection bulk supplier for pharma manufacturers

Fluphenazine Im Injection Suppliers & Bulk Manufacturers

Available Forms: Long-Acting Intramuscular Injection

Available Strengths: 25 mg/mL

Reference Brands: Prolixin Decanoate(US); Fluphenazine Decanoate(EU)

Category: Antipsychotropic Drugs

Fluphenazine IM Injection is available in Long-Acting Intramuscular Injection and strengths such as 25 mg/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Fluphenazine IM Injection is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Fluphenazine IM Injection can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Product Description: Fluphenazine IM injection, available in both short-acting and long-acting (decanoate) formulations, is FDA-approved in the United States for the treatment of chronic schizophrenia. In the EU, it is approved in select markets under national procedures. Regulatory submissions must meet GMP standards, ensure accurate dosing for depot formulations, and include safety data addressing extrapyramidal symptoms and neuroleptic malignant syndrome. EU applications must align with local pharmacovigilance requirements and psychiatric labeling standards. For global buyers seeking dossier-ready Fluphenazine IM injections and to explore other dosage forms and suppliers, visit Pharmatradz.com — your reliable B2B pharma sourcing platform.

Frequently Asked Questions

Yes, Fluphenazine IM Injection is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Fluphenazine IM Injection is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Risperidone Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Form: Long-Acting Injection

Reference Brands: Risperdal Consta(US &EU)

View Details
Zuclopenthixol Ong-Acting Im Injection (Depot)

Strength: 200 mg/mL, 500 mg/mL

Form: Long-acting IM Injection (Depot)

Reference Brands: Clopixol Depot®(US)

View Details
Zuclopenthixol Short-Acting Intramuscular Injection

Strength: 50 mg/mL

Form: Short-acting Intramuscular Injection

Reference Brands: Clopixol-Acuphase®

View Details
Zuclopenthixol Tablets

Strength: 10 mg, 25 mg, 40 mg

Form: Oral Tablets

Reference Brands: Clopixol®(EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.